Brief: Mainz Biomed Announces U.S. Extension Of Colofuture Study To Evaluate Integration Of Novel MRNA Biomarkers Into Coloalert
15/11/2022 14:51
Nov 15 (Reuters) - Mainz Biomed NV 4TO.F :
* MAINZ BIOMED ANNOUNCES U.S. EXTENSION OF COLOFUTURE STUDY
TO
EVALUATE INTEGRATION OF NOVEL MRNA BIOMARKERS INTO COLOALERT
* MAINZ BIOMED NV - EAARLY DETECT EXPECTED TO COMPLETE
ENROLLMENT
IN Q1 2023 WITH RESULTS IN 1H 2023
* MAINZ BIOMED - WILL DETERMINE IF ANY BIOMARKERS ARE
ELIGIBLE FOR
INCLUSION IN COMPANY'S U.S. PIVOTAL STUDY, WHICH IS ON TRACK TO
INITIATE IN Q4 2022
Source text for Eikon: ID:nGNX512CVS
Further company coverage: 4TO.F
Recent news on Quantum Cyber NV
See all newsBrief: Quantum Cyber To Proceed With Pending Litigation Against Adam Gefvert
Brief: Quantum Cyber NV Files Lawsuit Against White Diamond Research, Adam Gefvert And Stocktwits, Inc. In New York Supreme Court
Quantum Cyber jumps on SpaceX stake purchase plan
Brief: Quantum Cyber Signs Loi To Acquire An Estimated 43,000 Square Foot U.S.-Based Manufacturing Facility To Support Mass-Scale Autonomous Drone Production
Brief: Quantum Cyber NV - To Terminate ATM Sales Agreement With Maxim Effective June 7, 2026 - SEC Filing